One year cost effectiveness of sirolimus eluting stents compared with bare metal stents in the treatment of single native de novo coronary lesions: An analysis from the RAVEL trial

Heart

Volumn 91, Issue 4, 2005, Pages 507-512

  Van Hout, B A ^b   Serruys, Patrick W ^a   Lemos, P A ^c   Van Den Brand, M J B M ^a   Van Es, G A ^d   Lindeboom, W K ^d   Morice, M C ^e  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

^d Cardiolysis BV   (Netherlands)

^e INSTITUT CARDIOVASCULAIRE PARIS SUD   (France)

Author keywords

[No Author keywords available]

Indexed keywords

RAPAMYCIN; IMMUNOSUPPRESSIVE AGENT; METAL;

ANGIOGRAPHY; ARTICLE; BARE METAL STENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY STENT; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DOUBLE BLIND PROCEDURE; DRUG ELUTING STENT; FEMALE; FOLLOW UP; HEALTH CARE UTILIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MONEY; MULTICENTER STUDY; NETHERLANDS; OUTCOMES RESEARCH; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETREATMENT; STABLE ANGINA PECTORIS; SURVIVAL RATE; SURVIVAL TIME; UNSTABLE ANGINA PECTORIS; ANGIOCARDIOGRAPHY; CORONARY ARTERY OBSTRUCTION; COST BENEFIT ANALYSIS; DISEASE FREE SURVIVAL; ECONOMICS; RADIOGRAPHY; RESTENOSIS; STENT; SURFACE PROPERTY;

CORONARY ANGIOGRAPHY; CORONARY RESTENOSIS; CORONARY STENOSIS; COST-BENEFIT ANALYSIS; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; METALS; NETHERLANDS; SIROLIMUS; STENTS; SURFACE PROPERTIES;

EID: 15844430483     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/hrt.2004.034454     Document Type: Article

References (10)

1. Morice MC, Serruys PW, Sousa JE, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002;346:1773-80.
2. Moses JW, Leon MB, Popma JJ, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003;349:1315-23.
3. Schofer J, Schluter M, Gershlick AH, et al. Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS). Lancet 2003;362:1093-9.
4. Serruys PW, van Hout B, Bonnier H, et al. Randomised comparison of implantation of heparin-coated stents with balloon angioplasty in selected patients with coronary artery disease (Benestent II). Lancet 1998;352:673-81.
5. Serruys PW, de Bruyne B, Carlier S, et al. Randomized comparison of primary stenting and provisional balloon angioplasty guided by flow velocity measurement. Doppler endpaints balloon angioplasty trial Europe (DEBATE) II study group. Circulation 2000;102:2930-7.
6. Serruys PW, Unger F, Sousa JE, et al. Comparison of coronary-artery bypass surgery and stenting for the treatment of multivessel disease. N Engl J Med 2001;344:1117-24.
7. Van den Brand M, van Halem C, van den Brink F, et al. Comparison of costs of percutaneous transluminal coronary angioplasty and coronary bypass surgery for patients with angina pectoris. Eur Heart J 1990;11:765-71.
8. Ruygrok PN, Melkert R, Morel MA, et al. Does angiography six months after coronary intervention influence management and outcome? Benestent II investigators. J Am Coll Cardiol 1999;34:1507-11.
9. Efron B, Tibshirani RJ. An introduction to the bootstrap. Monographs on statistics and applied probability, vol 57. London: Chapman and Hall, 1993.
10. Lemos PA, Serruys PW, Sousa JE. Drug-eluting stents: cost versus clinical benefit. Circulation 2003;107:3003-7.